<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035631</url>
  </required_header>
  <id_info>
    <org_study_id>PREDICOP</org_study_id>
    <nct_id>NCT02035631</nct_id>
  </id_info>
  <brief_title>Prevention of Breast Cancer Recurrence Through Weight Control, Diet, and Physical Activity Intervention</brief_title>
  <acronym>PREDICOP</acronym>
  <official_title>Prevention of Breast Cancer Recurrence Through Weight Control, Diet, and Physical Activity Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Català d'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Català d'Oncologia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of our study is to assess the effect of a lifestyle intervention combining
      weight control, diet and physical activity on the risk of recurrences among breast cancer
      patients with non-metastatic tumours in terms of 5-year cumulative incidence of recurences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND/MAIN OBJECTIVE: The main purpose of our study is to assess the effect of a
      lifestyle intervention combining weight control, diet and physical activity on the risk of
      recurrences among breast cancer patients with non-metastatic tumours. As secondary objectives
      we aim to assess whether the proposed intervention is able to improve the overall survival or
      the disease-free survival, as well as quality of life of breast cancer patients. METHODOLOGY:
      This multicentric randomized controlled trial aims to include 2108 women (1054 per arm), aged
      up to 75 years, diagnosed with a non-metastatic breast cancer (stage I, II, IIIA) in the
      participating centres, whose standard treatment was completed within the last 3 months.
      Participants will be assigned to either an intervention or a control group, and followed for
      five years. Patients assigned to the control arm will continue with the usual care, including
      standard guidelines for weight control applied in the centre. Patients in the intervention
      group will be involved in a lifestyle program with two components. The dietary part will aim
      to achieve a calorie reduction while maintaining nutritional quality; the physical activity
      part will include supervised sessions of moderate intensity. Data will be analyzed on an
      intention to treat basis using time-toevent analysis. HYPOTHESES: We expect a significant
      reduction in the 5-year cumulative incidence of recurrences (primary outcome) in the
      intervention group. Furthermore, as secondary outcomes, we expect a significant increase in
      overall survival and an improvement of quality of life of patients included in the
      intervention arm.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to local and distant recurrence</measure>
    <time_frame>5 years from recruitment day</time_frame>
    <description>Time between recruitment date and local and distant recurrence date or end of the 5-year follow-up which ever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time between recruitment date and death date or end of 5-year follow-up which ever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time between recruitment date and recurrence (local or distant) or death or end of 5-year follow-up which ever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline, one year and three years</time_frame>
    <description>Quality of life assessments using the SF36, the FACIT (fatigue questionnaire) and the HADS (Anxiety and depression)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in biomarkers</measure>
    <time_frame>Baseline and one year</time_frame>
    <description>Biomarkers related to:
sex hormone profile,
dietary intake,
insulin resistance,
inflammation process
and any biomarker possibly related to the progression of the disease.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lifestyle intervention combining weight control, diet and physical activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal intervention</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Minimal diet intervention and minimal physical activity intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physical activity</intervention_name>
    <description>The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Minimal diet intervention</intervention_name>
    <description>Some basic diet recommendations</description>
    <arm_group_label>Minimal intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Minimal physical activity intervention</intervention_name>
    <description>Some basic recommendations on physical activity</description>
    <arm_group_label>Minimal intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  incident primary breast cancer (ICD-O C50)

          -  stage at diagnosis I, II, IIIA (or T1-3, N0-N2, M0)

          -  age at diagnosis below 76 years

          -  within 3 months since completion of standard treatment (excluding hormonal therapy)
             and within 15 months since the diagnosis of the disease

        Exclusion Criteria:

          -  morbid obesity (BMI &gt;40kg/m²) or underweight (BMI &lt;18kg/m²)

          -  ischemic heart disease (coronary syndrome, unstable angina or myocardial infarction)
             or cerebrovascular incident (ischemic or hemorrhagic) during the previous 12 months

          -  diabetes (only if unstable - glycosylated haemoglobin &gt;9%)

          -  current medical or surgical treatment to lose weight

          -  mental illness that would prevent the patient from carrying out the intervention

          -  logistical factors which would prevent the patient from carrying out the intervention
             (distance to travel, work or family commitments)

          -  pregnant or planning pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatriz Cirauqui Cirauqui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut d'Investigació Germans Trias i Pujol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Del Barco Berron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vanesa Ortega Cebrián, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Angeles Arcusa Lanza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consorci Sanitari de Terrassa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Agudo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Català d'Oncología - L'Hospitalet (ICO)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Agudo, MD-PhD</last_name>
    <phone>+34 932607401</phone>
    <email>a.agudo@iconcologia.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noemie Travier, MSc</last_name>
    <phone>+34 932607401</phone>
    <email>ntravier@iconcologia.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundació Institut d'Investigació Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatriz Cirauqui Cirauqui, MD</last_name>
      <phone>+34 934978925</phone>
      <email>bcirauqui@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Beatriz Cirauqui Cirauqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Agudo, MD</last_name>
      <phone>+34 932607401</phone>
      <email>a.agudo@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Antonio Agudo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Angeles Arcusa Lanza, MD</last_name>
      <phone>+34 937003612</phone>
      <email>aarcusa@cst.cat</email>
    </contact>
    <investigator>
      <last_name>Maria Angeles Arcusa Lanza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vanesa Ortega Cebrián, MD</last_name>
      <phone>+34 934894350</phone>
      <email>vortega@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Vanesa Ortega Cebrián, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonia Del Barco Berron, MD</last_name>
      <phone>+34 972225834</phone>
      <email>sdelbarco@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Sonia Del Barco Berron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Motor Activity</keyword>
  <keyword>Diet</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

